Trials / Terminated
TerminatedNCT00652158
A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Millennium Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1 clinical trial designed to evaluate increasing durations of MLN8054 oral dosing in patients with advanced malignancies. MLN8054 will be given once daily for 4 to 7 consecutive days per week for 2 to 3 weeks. Following the 2- to 3-week treatment period there will be a 2 week recovery period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MLN8054 | 10 mg doses of MLN8054 were given orally once daily following a schedule of "5 days on/2 days off/5 days on" repeated every 28 days |
Timeline
- Start date
- 2006-04-01
- Primary completion
- 2008-03-01
- Completion
- 2008-04-01
- First posted
- 2008-04-03
- Last updated
- 2013-09-23
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT00652158. Inclusion in this directory is not an endorsement.